Multiparametric MRI enables for differentiation of different degrees of malignancy in two murine models of breast cancer.
LA-ICP-MS
MRI
oncologic imaging
tumor heterogeneity
tumor vasculature
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
08
2022
accepted:
11
10
2022
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
The objective of this study was to non-invasively differentiate the degree of malignancy in two murine breast cancer models based on identification of distinct tissue characteristics in a metastatic and non-metastatic tumor model using a multiparametric Magnetic Resonance Imaging (MRI) approach. The highly metastatic 4T1 breast cancer model was compared to the non-metastatic 67NR model. Imaging was conducted on a 9.4 T small animal MRI. The protocol was used to characterize tumors regarding their structural composition, including heterogeneity, intratumoral edema and hemorrhage, as well as endothelial permeability using apparent diffusion coefficient (ADC), T1/T2 mapping and dynamic contrast-enhanced (DCE) imaging. Mice were assessed on either day three, six or nine, with an i.v. injection of the albumin-binding contrast agent gadofosveset. Ex vivo validation of the results was performed with laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS), histology, immunhistochemistry and electron microscopy. Significant differences in tumor composition were observed over time and between 4T1 and 67NR tumors. 4T1 tumors showed distorted blood vessels with a thin endothelial layer, resulting in a slower increase in signal intensity after injection of the contrast agent. Higher permeability was further reflected in higher K Multiparametric MRI as presented in this study enables for the estimation of malignant potential in the two studied tumor models
Identifiants
pubmed: 36408159
doi: 10.3389/fonc.2022.1000036
pmc: PMC9667047
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1000036Informations de copyright
Copyright © 2022 Gerwing, Hoffmann, Kronenberg, Hansen, Masthoff, Helfen, Geyer, Wachsmuth, Höltke, Maus, Hoerr, Krähling, Hiddeßen, Heindel, Karst, Kimm, Schinner, Eisenblätter, Faber and Wildgruber.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Magn Reson Med. 2008 Dec;60(6):1313-20
pubmed: 19030165
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.2
pubmed: 18432775
Exp Biol Med (Maywood). 2012 Nov;237(11):1273-80
pubmed: 23239438
Sci Rep. 2017 Aug 11;7(1):7952
pubmed: 28801575
Cancer Imaging. 2018 Nov 8;18(1):41
pubmed: 30409175
J Magn Reson Imaging. 2017 Feb;45(2):440-449
pubmed: 27367863
J Biophotonics. 2020 Jul;13(7):e202000005
pubmed: 32219996
J Cardiovasc Magn Reson. 2017 Oct 9;19(1):75
pubmed: 28992817
Mol Pharm. 2020 Jan 6;17(1):109-117
pubmed: 31816245
Breast Care (Basel). 2017 Dec;12(6):391-394
pubmed: 29456471
Quant Imaging Med Surg. 2019 Apr;9(4):671-680
pubmed: 31143658
Invest Radiol. 2019 Feb;54(2):118-128
pubmed: 30379727
J Exp Clin Cancer Res. 2020 May 27;39(1):95
pubmed: 32460897
Annu Rev Cancer Biol. 2020 Mar;4(1):99-119
pubmed: 34164589
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1208-15
pubmed: 15752903
PLoS One. 2017 May 18;12(5):e0177903
pubmed: 28542297
Sci Rep. 2020 May 5;10(1):7598
pubmed: 32371907
Anal Chem. 2021 Nov 30;93(47):15720-15727
pubmed: 34784194
Integr Biol (Camb). 2015 Oct;7(10):1120-34
pubmed: 25959051
J Nucl Med. 2017 May;58(5):815-820
pubmed: 28126891
Methods Mol Biol. 2014;1180:31-43
pubmed: 25015141
Insights Imaging. 2012 Dec;3(6):573-89
pubmed: 23093486
Magn Reson Med. 2012 Jan;67(1):201-9
pubmed: 21630350
Biochemistry (Mosc). 2017 Apr;82(4):413-425
pubmed: 28371598
Eur Radiol. 2020 Mar;30(3):1334-1341
pubmed: 31705255
Cancer Res. 2020 Aug 15;80(16):3424-3435
pubmed: 32595135
Br J Cancer. 2009 Mar 24;100(6):865-9
pubmed: 19240721
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Cell Rep. 2021 Apr 13;35(2):108993
pubmed: 33852863
Atherosclerosis. 2018 Aug;275:400-408
pubmed: 29735362
Z Med Phys. 2008;18(2):85-90
pubmed: 18705608
PLoS One. 2015 Jun 22;10(6):e0131095
pubmed: 26098849
Eur Radiol. 2019 Jan;29(1):213-223
pubmed: 29922932
J Magn Reson Imaging. 2002 Oct;16(4):407-22
pubmed: 12353256
Medicine (Baltimore). 2018 Sep;97(37):e12246
pubmed: 30212958
Nat Rev Clin Oncol. 2011 Aug 23;8(10):587-96
pubmed: 21862978
NMR Biomed. 2017 Feb;30(2):
pubmed: 28008670
PLoS One. 2012;7(3):e33241
pubmed: 22457748
Korean J Radiol. 2014 Sep-Oct;15(5):591-604
pubmed: 25246820
Br J Cancer. 2021 Jul;125(2):164-175
pubmed: 33824479
Oncogene. 2017 Oct 5;36(40):5639-5647
pubmed: 28581516
Sci Rep. 2022 Apr 20;12(1):6523
pubmed: 35444193
BMC Cancer. 2008 Aug 09;8:228
pubmed: 18691423
J Nucl Med. 2015 Mar;56(3):450-6
pubmed: 25678492
Sci Rep. 2017 Dec 6;7(1):17038
pubmed: 29213099
Eur J Cancer. 2012 Mar;48(4):425-31
pubmed: 22226479
Cancers (Basel). 2021 Nov 23;13(23):
pubmed: 34884988
Mol Imaging Biol. 2017 Apr;19(2):225-232
pubmed: 27541025
Nat Biotechnol. 2008 Mar;26(3):303-4
pubmed: 18327243
Biomedicines. 2020 Oct 13;8(10):
pubmed: 33066169
Cancers (Basel). 2020 Mar 07;12(3):
pubmed: 32156052
Cancer Res. 2011 May 1;71(9):3364-76
pubmed: 21415165
Clin Cancer Res. 2017 Mar 15;23(6):1461-1470
pubmed: 27663591
Nat Rev Clin Oncol. 2019 Jul;16(7):442-458
pubmed: 30718844
Br J Cancer. 2014 Dec 9;111(12):2205-13
pubmed: 25268373
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Clin Cancer Res. 2011 Oct 1;17(19):6250-6261
pubmed: 21844011
Cancer Res. 2019 Aug 1;79(15):3952-3964
pubmed: 31186232
Magn Reson Med. 2018 Feb;79(2):1090-1100
pubmed: 28474481
NMR Biomed. 2021 Mar;34(3):e4454
pubmed: 33325086
Cancer Res. 1992 Mar 15;52(6):1399-405
pubmed: 1540948
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Analyst. 2012 Apr 7;137(7):1527-37
pubmed: 22314636